Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, The Norwegian Radium Hospital, University in Oslo, Norway.
J Immunother. 2010 Apr;33(3):272-8. doi: 10.1097/CJI.0b013e3181c54991.
We have earlier shown that the 9.2.27 Pseudomonas Exotoxin A (PE) immunotoxin (IT) efficiently kills melanoma cells through inhibition of protein synthesis followed by some morphologic and biochemical features of apoptosis, a different cell killing mechanism than the one caused by Dacarbazine (DTIC), a chemotherapeutic drug used to treat malignant melanoma. To examine whether induced DTIC resistance also is a determining factor for the effectiveness of 9.2.27PE IT, we developed a DTIC resistant subline, FEMX-200DR, from the DTIC sensitive cell line FEMX. The cell variants were treated with 9.2.27PE, an IT binding to the high molecular weight-melanoma associated antigen (HMW-MAA) expressed on most malignant melanoma cells. The IT was equally effective in killing the FEMX-200DR and the FEMX cells, and the cell death was primarily caused by inhibition of protein synthesis. The DNA repair enzyme and apoptotic marker PARP, a substrate of caspase-3, was inactivated, although we observed only a minor activation of caspase-3 and caspase-8, intracellular proteases involved in apoptosis. In addition to being DTIC resistant, the FEMX-200DR cells were also more resistant to apoptosis than the parent cells as a 3 times higher concentration of the apoptotic inducer Staurosporine was needed to obtain IC50. Furthermore, in early passage malignant melanoma cell lines established from lymph node metastases, the 9.2.27PE caused a time-dependent and dose-dependent decrease in cell viability independent of their DTIC sensitivity. These findings show that the 9.2.27PE IT efficiently can cause cell death in malignant melanoma cells independent of their level of resistance to apoptosis and DTIC.
我们之前已经证明,9.2.27 假单胞菌外毒素 A(PE)免疫毒素(IT)通过抑制蛋白质合成有效地杀死黑色素瘤细胞,随后出现一些凋亡的形态和生化特征,这是一种与达卡巴嗪(DTIC)不同的细胞杀伤机制,DTIC 是一种用于治疗恶性黑色素瘤的化疗药物。为了研究诱导的 DTIC 耐药是否也是 9.2.27PE IT 有效性的决定因素,我们从 DTIC 敏感细胞系 FEMX 中开发了一个 DTIC 耐药亚系 FEMX-200DR。细胞变体用 9.2.27PE 处理,该 IT 结合到大多数恶性黑色素瘤细胞上表达的高分子量-黑色素瘤相关抗原(HMW-MAA)。该 IT 对 FEMX-200DR 和 FEMX 细胞同样有效,细胞死亡主要是由于蛋白质合成的抑制。DNA 修复酶和凋亡标志物 PARP,一种 caspase-3 的底物,失活,尽管我们仅观察到 caspase-3 和 caspase-8 的轻微激活,caspase-3 和 caspase-8 是参与凋亡的细胞内蛋白酶。除了对 DTIC 耐药外,FEMX-200DR 细胞对凋亡的耐药性也高于亲本细胞,因为需要 3 倍更高浓度的凋亡诱导剂 Staurosporine 才能获得 IC50。此外,在从淋巴结转移建立的早期传代恶性黑色素瘤细胞系中,9.2.27PE 导致细胞活力随时间和剂量依赖性下降,与它们对 DTIC 的敏感性无关。这些发现表明,9.2.27PE IT 能够有效地导致恶性黑色素瘤细胞死亡,而与它们对凋亡和 DTIC 的耐药性水平无关。